Future directions for research on Silybum marianum for cancer patients

Integrative Cancer Therapies

Volumn 6, Issue 2, 2007, Pages 166-173

  Sagar, Stephen M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cancer; Milk thistle; Oncology; Research; Silymarin

Indexed keywords

CISPLATIN; DOXORUBICIN; IRINOTECAN; ISOSILYBIN A; ISOSILYBIN B; PALMETTO EXTRACT; PLACEBO; PLANT EXTRACT; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILIPHOS; SILYBIN A; SILYBIN B; SILYBUM MARIANUM EXTRACT; SILYMARIN; TAXIFOLIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; CANCER; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG UPTAKE; ESTROGEN ACTIVITY; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MEDICINAL PLANT; NONHUMAN; PLAMETTO; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY CONTROL; REVIEW; SAFETY; SILYBUM MARIANUM; TISSUE REGENERATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMEDICAL RESEARCH; CLINICAL TRIALS; FORECASTING; HUMANS; MILK THISTLE; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; QUALITY CONTROL;

EID: 34249871659     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735407301566     Document Type: Review

References (40)

1. Adams LS, Seeram NP, Hardy ML, Carpenter C., Heber D. Analysis of the interactions of botanical extract combinations against the viability of prostate cancer cell lines. eCAM. 2006 ; 3: 117-124.
2. Sullivan D., Crowley R. Development and validation of analytical methods for dietary supplements. Toxicology. 2006 ; 221: 28-34.
3. AOAC International. The scientific association committed to worldwide confidence in analytical results. Available at: http://www.aoac.org/. Accessed February 20, 2007.
4. Sander LC, Sharpless KE, Wise SA Dietary supplement standard reference materials. Life Sci. 2006 ; 78: 2044-2048.
5. Blumenthal M., Milot B. Bioassays for testing activity and bioavailability of botanical products. HerbalGram. 2004 ; 63: 48-51.
6. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006 ; 354: 557-566.
7. Kroll DJ, Oberlies NH The impact of newly proposed dietary supplement manufacturing guidelines on patient safety and clinical trials outcomes. Focus on Alternative and Complementary Therapies. 2003 ; 8: 302-306.
8. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007 ; 25: 139-146.
9. Sridar C., Goosen TC, Kent UM, Williams JA, Hollenberg PF Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 2004 ; 32: 587-594.
10. Barnes S., Prasain JK, Wang C-C., Moore DR Applications of LC-MS in the study of the uptake, distribution, metabolism and excretion of bioactive polyphenols from dietary supplements. Life Sci. 2006 ; 78: 2054-2059.
11. Foster BC, Arnason T., Briggs CJ Natural health products and drug disposition. Ann Rev Pharmacol Toxicol. 2005 ; 45: 203-226.
12. Kroes R., Walker R. Safety issues of botanicals and botanical preparations in functional foods. Toxicology. 2004 ; 198 ; 213-220.
13. Srinivasan VS Challenges and scientific issues in the standardization of botanicals preparations. United States Pharmacopeia's dietary supplement program-a public health program. Life Sci. 2006 ; 28: 2039-2043.
14. Swanson CA Suggested guidelines for articles about botanical dietary supplements. Am J Clin Nutr. 2002 ; 75: 8-10.
15. Piersen CE, Booth NL, Sun Y., et al. Chemical and biological characterization and clinical evaluation of botanical dietary supplements: a phase I red clover extract as a model. Curr Med Chem. 2004 ; 11: 1361-1374.
16. Davis-Searles PR, Nakanishi Y., Kim NC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 2005 ; 65: 4448-4457.
17. Singh RP, Agarwal R. Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets. 2006 ; 7: 345-354.
18. Dvorak Z., Kosina P., Walterova D., Simanek V., Bachieda P., Ulrichova J. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett. 2003 ; 137: 201-212.
19. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal. 2002 ; 4: 655-663.
20. Katiyar SK Silymarin and skin cancer prevention: antiinflammatory, antioxidant and immunomodulatory effects. Int J Oncol. 2005 ; 26: 169-176.
21. Shi J., Zhu L., Liu S., Xie WF A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005 ; 92: 607-612.
22. Huseini HF, Larijani B., Heshmat R., et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006 ; 20: 1036-1039.
23. Chang CK, Ulrich CM Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia. 2003 ; 46: 595-607.
24. Hoh C., Boocock D., Marczylo T., et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences Clin Cancer Res. 2006 ; 12: 2944-2950.
25. Cavalieri EL, Rogan EG A unifying mechanism in the initiation of cancer and other diseases by catechol quinones. Ann NY Acad Sci. 2004 ; 1028: 247-257.
26. Lee KH, Xiao Z. Lignans in treatment of cancer and other diseases. Phytochemistry Reviews. 2003 ; 2: 341-362.
27. Tyagi A., Bhatia N., Condon MS, Bosland MC, Agarwal C., Agarwal R. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate. 2002 ; 53: 211-217.
28. Singh RP, Deep G., Chittezhath M., et al. Effect of Silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst. 2006 ; 98: 846-855.
29. Singh RP, Agarwal R. Prostate cancer prevention by silibinin; Curr Cancer Drug Targets. 2004 ; 4: 1-11.
30. Tyagi AK, Agarwal C., Chan DC, Agarwal R. Synergistic anticancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004 ; 11: 493.
31. Scambia G., De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer. 1996 ; 32A: 877-882.
32. Bokemeyer C., Fels LM, Dunn T., et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer. 1996 ; 74: 2036-2041.
33. Gagnier JJ, Boon H., Rochon P., Moher D., Barnes J., Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006 ; 144: 364-367.
34. Malewicz B., Wang Z., Jiang C., Guo J., Cleary MP, Grande JP Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements. Carcinogenesis. 2006 ; 27: 1739-1747.
35. Fraschini F., Demartini G., Esposti D. Pharmacology of silymarin. Clin Drug Invest. 2002 ; 22: 51-65.
36. Dietzmann J., Thiel U., Ansorge S., Neumann KH, Tager M. Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. Free Radic Biol Med. 2002 ; 33: 1347-1354.
37. Gaedeke J., Fels LM, Bokemeyer C., et al. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant. 1996 ; 11: 55-62.
38. Ramadan LA, Abu-Senna GM, Roushdy HM, Amin NE, El-Deshw OA Protective role of silymarin against gamma radiation effects of lipids, urea and creatinine serum levels. Acta Pharm. 2002 ; 52: 161-170.
39. Ramadan LA, Roushdy HM, Abu GM, Amin NE, El-Deshw OA Radioprotective effect of silymarin against radiation induced hepatotoxicity. Pharmacol Res. 2002 ; 45: 447-452.
40. Ladas EJ, Cheng B., Hughes D., et al. Milk thistle (Silybum marianum) is associated with reductions in liver function tests (LFTs) in children undergoing therapy for acute lymphoblastic leukemia (ALL) (abstract D045). Paper presented at: 3rd International Conference of the Society for Integrative Oncology ; November 11, 2006 ; Boston, Mass.